Cocrystal Pharma Inc
(NASDAQ : COCP)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Generic
symbolcompany%chnglast%shortavg$volume
AGNAllergan plc
0.27%139.042.8%$460.22m
ZTSZoetis, Inc. Class A
2.26%95.371.9%$259.47m
TEVATeva Pharmaceutical Industries Limited Sponsored ADR
4.05%17.982.1%$189.62m
MYLMylan N.V.
1.02%31.843.2%$142.47m
TXMDTherapeuticsMD, Inc.
-1.40%5.6525.3%$14.68m
RDYDr. Reddy's Laboratories Ltd. Sponsored ADR
-4.54%36.002.0%$10.26m
TAROTaro Pharmaceutical Industries Ltd.
0.56%105.026.4%$7.12m
LFVNLifeVantage Corporation
1.28%15.883.3%$3.05m
PETXAratana Therapeutics, Inc.
2.55%4.428.5%$2.91m
KINKindred Biosciences, Inc.
3.44%10.830.3%$2.80m
ABEOAbeona Therapeutics, Inc.
2.00%6.637.8%$2.50m
JAGXJaguar Animal Health, Inc.
-0.42%0.249.8%$0.09m
CPHIChina Pharma Holdings, Inc.
-3.05%0.270.1%$0.06m

Company Profile

Cocrystal Pharma, Inc. is a clinical stage biotechnology company, which engages in discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of Hepatitis C. Phase 1b studies in Hepatitis C infected patients showed the largest reduction in viral load of any non-neoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 6 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the company has a pipeline of early preclinical programs. Cocrystal Pharma was founded on January 2, 2014 and is headquartered in Tucker, GA..